Development and Validation of a Nomogram Model for Prognostic Assessment in Primary Cervical Squamous Cell Carcinoma with Serum SCC Antigen Levels ≥10 ng/mL Using Inflammatory Biomarkers and Clinical Variables - Summary - MDSpire
Advertisement
Development and Validation of a Nomogram Model for Prognostic Assessment in Primary Cervical Squamous Cell Carcinoma with Serum SCC Antigen Levels ≥10 ng/mL Using Inflammatory Biomarkers and Clinical Variables
To develop and validate a multivariable prognostic model for patients with primary cervical cancer and elevated SCC-Ag levels (≥10 ng/mL), integrating inflammatory markers and clinical variables.
Key Findings:
Pretreatment SCC-Ag levels ≥10 ng/mL are associated with poor survival outcomes in cervical cancer.
Inflammatory markers and hematological indices can provide significant prognostic information.
The developed nomogram effectively stratifies risk and aids in personalized treatment planning.
Interpretation:
The nomogram offers a refined tool for predicting outcomes in patients with high SCC-Ag levels, potentially improving individualized treatment strategies.
Limitations:
Retrospective design may introduce selection bias.
External validation cohort was small and limited to a single center.
Conclusion:
The study successfully developed a prognostic nomogram that integrates inflammatory and clinical factors for patients with primary cervical cancer and high SCC-Ag levels, enhancing risk stratification and treatment personalization.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
